Friday, 15 Dec 2017

You are here

Concomitant Septic Arthritis and Crystalline Arthropathy

I joined a poster tour this morning on the topic of infections and was intrigued by an abstract titled, Coexistence of septic and crystal-induced arthritis: a diagnostic challenge (#0560, Y Garcia-Mira, et al).

The authors sought to describe the characteristics of patients with concurrent septic and crystal arthritis through a retrospective analysis of patients with the concomitant diagnoses between 1985-2015 at a university hospital in Spain.  

Out of 123 patients with septic arthritis, 20.3% (25) had concurrent crystalline arthritis. All patients had positive bacterial culture (blood and/or synovial fluid) and crystals in synovial fluid. The majority (68%) were males and average age was 67 years. Risk factors identified were diabetes in 24%, use of diuretics in 24%, and CKD in 16% including 2 on dialysis and 4 with history of kidney transplant. There was a delay to diagnosis on average of 14 days and the most commonly affected joint was the knee followed by the foot and hip.

As far as types of crystalline arthropathy, 60% had MUS, 20% CPPD and 8% hydroxyapatite. 32% had positive gram stain and 88% had positive synovial fluid culture. Blood cultures were positive in 32%. Surgical debridement was done in 32% and mortalitiy was 8%.

I found the 20% incidence of concurrent septic arthritis and crystal disease to be quite high, but nonetheless this is something to consider especially in elderly males with certain co-morbidities, and reminds us that synovial fluid should always be examined for crystals and infection.  

Add new comment

More Like This

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations. 

RheumNow ACR 2017 Awards

The Annual Meeting of the American College of Rheumatology is a gargantuan educational and professional event that is on nearly everyone's radar each year. RheumNow had an expansive effort to cover this meeting and you can review the work of our faculty at ACR17.RheumNow.com.  But we have decided to take this one step further and today we are announcing our 2017 RheumNow ACR Awards.